Dr. Irshad Ahmad

Dr. Irshad Ahmad

ASSOCIATE PROFESSOR – CHEMISTRY

Department of Mathematics and Natural Sciences, School of Arts and Sciences, American University of Ras Al Khaimah, Ras Al Khaimah, United Arab Emirates

Biography

Office No.: C21

Phone: Tel. Ext. 1270

Email: iahmad@aurak.ac.ae

Biography

Dr. Irshad Ahmad joined the American University of Ras Al Khaimah in spring 2011 as an Assistant Professor of Chemistry. He received the master’s degree in chemistry from Jiwaji University in 1999. Subsequently acquired significant pharmaceutical industrial experience and developed cardio-selective beta-blocker drug molecule. He joined Central Salt and Marine Chemical Research Institute and Bhavnagar University under the sponsored project of DST and CSIR as a senior research fellow and received his PhD degree in chemistry in 2006. Subsequently, he accepted an invited scientist position in Korea Research Institute of Chemical Technology, South Korea and contributed his expertise in the field of Nanotechnology. Dr. Irshad is a recipient of prestigious European fellowships (NWO-Rubicon & FCT) and he joined Van’t Hoff Institute for Molecular Sciences, University of Amsterdam, The Netherlands as a NWO Rubicon fellow (Netherlands Organization for Scientific Research, the Dutch Science Foundation), he acquired expertise in the field of supramolecular chemistry.

Afterward, he moved to the Leibniz Institute for Surface Modification, Leipzig, Germany under the Deutsche Forschungsgemeinschaft Grant. Dr. Irshad developed “Novel ultra-fast metathesis catalyst” for the production of high quality alternating copolymers. Subsequently Dr. Irshad, joined Department of Chemistry and Biochemistry, Stephenson Life Science Research Center, University of Oklahoma, USA as a postdoctoral research associate.  He developed strategies for the novel environmentally friendly reactions for the production of value added chemicals from biomass.

Dr. Irshad specialized in the area of chemistry, bridging the traditional disciplines of inorganic, organic and bio-organic chemistry. He contributed US and European patent for green and clean technology development. He has published peer-reviewed international research articles in the American Chemical Society (ACS), Royal Society of Chemistry (RSC) Cambridge, Elsevier Science, Wiley, and Springer journals. He has presented his research at several scientific conferences worldwide and received awards.

Research and Publication

Research Interest:

Asymmetric catalysis, Biotechnology, Metathesis, Material science, Nanotechnology, Pharmaceutical, Renewable energy and Supramolecular chemistry

Book:

Asymmetric Homogeneous and Heterogeneous Catalysts: An Approach to the Synthesis of Chiral Drug Intermediates by Scholars Press, Germany. 2013, ISBN: 978-3-639-51138-3

Membership:   

• American Chemical Society (ACS), USA
• The Royal Society of Chemistry, Cambridge, UK

Patents:

• United States Patent 7,235,676, H. Khan, S. H. R. Abdi, R. I. Kureshy, S. Singh, I. Ahmad, R. V. Jasra, P. K. Ghosh, ‘Catalytic process for the preparation of epoxides from alkenes.

• Patent Cooperation Treaty (PCT) WO/2005/095370, N. H. Khan, S. H. R. Abdi, R. I. Kureshy, S. Singh, I. Ahmad, R. V. Jasra, P. K. Ghosh. An improved catalytic process for the preparation of epoxides from alkenes.

• European Patent EP 1732910 A1, N. H. Khan, S. H. R. Abdi, R. I. Kureshy, S. SinghA, I. Ahmad, R. V. Jasra, P. K. Ghosh, An improved catalytic process for the preparation of epoxides from alkenes. 

Publications:

• Pramoda, U. Gupta, I. Ahmad, R. Kumar, C.N.R. Rao, Assemblies of Covalently Cross-linked Nanosheets of MoS2 and of MoS2-RGO: Synthesis and Novel Properties, Journal of Materials Chemistry A, 4, 2016, 8989.

• Shagufta, I. Ahmad, Recent insight into the biological activities of synthetic xanthone derivatives, European Journal of Medicinal Chemistry, 116, 2016, 267.

• Ahmad, Shagufta, Recent Development in Steroidal and Non-steroidal Aromatase Inhibitors for the Chemoprevention of Estrogen dependent Breast Cancer, European Journal of Medicinal Chemistry, 102, 2015, 375.

• Ahmad, Shagufta, Sulfones: An important class of organic compounds with diverse biological activities, International Journal of Pharmacy and Pharmaceutical Sciences, 7, 3, 2015, 19.

• Kumar, K. Gopalakrishnan, I. Ahmad, and C. N. R. Rao, BN-Graphene Composites Generated by Covalent Cross-Linking with Organic Linkers, Advanced Functional Materials, 25, 37, 2015, 5910.

• Kumar, D. Raut, I. Ahmad,   U. Ramamurty,   T. K. Maji and   C. N. R. Rao. Functionality preservation with enhanced mechanical integrity in the nanocomposites of the metal–organic framework, ZIF-8, with BN nanosheets, Materials Horizons, 1, 2014, 513.

• R. Buchmeiser, I. Ahmad, V. Gurram and P. S. Kumar, Pseudo-Halide and Nitrate Derivatives of Grubbs and Grubbs_Hoveyda Initiators: Some Structural Features Related to the Alternating Ring-Opening Metathesis Copolymerization of Norborn-2-ene with Cyclic Olefins, Macromolecule, 44 (11), 2011, 4098.

• Ahmad, G. Chapman and K. M. Nicholas, Sulfite-Driven, Oxorhenium-Catalyzed Deoxydehydration of Glycols, Organometallics, 30 (10), 2011, 2810.

• Vkuturi, G. Chapman, I. Ahmad, K. M. Nicholas, Rhenium-Catalyzed Deoxydehydration of Glycols by Sulfite, Inorganic Chemistry, 49, 2010, 4744.

• I. Kureshy, I. Ahmad, K. Pathak, N. H. Khan, S. H. R. Abdi, H. C. Bajaj, Solvent- free microwave synthesis of aryloxypropanolamines by ring opening of aryloxy epoxides, Research Letters in Organic Chemistry, 2009, Article ID 109717, doi:10.1155/2009/109717.

• I. Kureshy, I. Ahmad, K. Pathak, N. H. Khan, S. H. R. Abdi, R. V. Jasra, Sulfonic acid functionalized mesoporous SBA-15 as an efficient and recyclable catalyst for the synthesis of chromenes from chromanols, Catalysis Communications 10, 2009, 572.

• Pathak, I. Ahmad, S. H. R. Abdi, R. I. Kureshy, N. H. Khan, R. V. Jasra, The synthesis of silica-supported chiral BINOL: Application in Ti-catalyzed asymmetric addition of diethylzinc to aldehydes, Journal of Molecular Catalysis A-Chemical 280, 2008, 106.

• Kluwer, I. Ahmad, J. N. H. Reek, Improved synthesis of monodentate and bidentate 2- and 3-pyridylphosphines, Tetrahedron Letter 48, 2007, 2999.

• Pathak, I. Ahmad, S. H. R. Abdi, R. I. Kureshy, N. H. Khan, R. V. Jasra, Oxidative Kinetic Resolution of racemic Secondary Alcohols catalyzed by recyclable Dimeric Mn(III) salen catalysts, Journal of Molecular Catalysis A-Chemical 274, 2007, 120.

• I. Kureshy, I. Ahmad, N. H. Khan, S. H. R. Abdi, K. Pathak, R. V. Jasra, Easily Recyclable Chiral Polymeric Mn (salen) Complex for Oxidative Kinetic resolution of Racemic Secondary Alcohols, Chirality, 19, 2007, 352.

• Pathak, A. P. Bhatt, S. H. R. Abdi, R. I. Kureshy, N. H. Khan, I. Ahmad, R. V. Jasra, Enantioselective phenylacetylene addition to aromatic aldehydes and ketones catalyzed by recyclable polymeric Zn(II) salen complex, Chirality, 19, 2007, 1.

• I. Kureshy, I. Ahmad, N. H. Khan, S. H. R. Abdi, K. Pathak, R. V. Jasra, Chiral Mn (III) salen complexes covalently bonded on modified MCM-41 and SBA-15 as efficient catalysts for enantioselective epoxidation of non- functionalized alkenes, Journal of Catalysis A-Chemical, 238, 2006, 134.

• Pathak, A. P. Bhatt, S. H. R. Abdi, R. I. Kureshy, N. H. Khan, I. Ahmad, R. V. Jasra Enantioselective addition of diethylzinc to aldehydes using immobilized chiral BINOL-Ti complex on ordered mesoporous silicas, Tetrahedron: Asymmetry,17, 2006, 1506.

• I. Kureshy, I. Ahmad, N. H. Khan, S. H. R. Abdi, K. Pathak, R. V. Jasra, Encapsulation of chiral MnIII (salen) complex in ordered mesoporous silicas: An approach Towards heterogenizing asymmetric Epoxidation catalysts for non-Functionalized alkenes, Tetrahedron: Asymmetry 16, 2005, 3562.

• I. Kureshy, I. Ahmad, N. H. Khan, S. H. R. Abdi, S. Singh, P. H. Pandia, R. V. Jasra, New immobilized chiral Mn(III) salen complexes on pyridine N-Oxide Modified MCM-41as effective catalysts for epoxidation of nonfunctionalized Alkenes, Journal of Catalysis A- Chemical 235 , 2005, 28.

• Pathak, A. P. Bhatt, S. H. R. Abdi, R. I. Kureshy, N. H. Khan, I. Ahmad, R. V. Jasra Enantioselective addition of diethylzinc to aldehydes using immobilized chiral BINOL-Ti complex on ordered mesoporous silicas, Tetrahedron: Asymmetry,17, 2006, 1506.

• I. Kureshy, S. Singh, N. H. Khan, S. H. R. Abdi, I. Ahmad, A. Bhatt, R. V. Jasra, Improved catalytic activity of homochiral dimeric cobalt salen hydrolytic kinetic resolution of terminal racemic epoxides, Chirality, 17, 2005, 1.

• I. Kureshy, S. Singh, N. H. Khan, S. H. R. Abdi , I. Ahmad, .Bhatt, R. V. Jasra, Environment friendly protocol for enantioselective epoxidation of non-functionalized Alkenes catalyzed by recyclable homochiral dimeric Mn(III)salen complexes with hydrogen peroxide and UHP adduct as Oxidants, Catalysis Letters, 107, 2005, 127.

• I. Kureshy, N. H. Khan, S. H. R. Abdi, I. Ahmad, S. Singh, and R. V. Jasra, Dicationic chiral Mn (III) Salen complex exchange in the interlayers of Montmorillonite clay: a heterogeneous enantioselective catalyst for epoxidation of non-functionalised alkenes, Journal of Catalysis, 221, 2004, 234.

• I. Kureshy, N. H. Khan, S. H. R. Abdi, S. Singh, I. Ahmad, R. V. Jasra, Catalytic asymmetric epoxidation of non-functionalised alkenes using polymeric Mn(III)Salen as catalysts and NaOCl as oxidant, Journal of Molecular Catalysis A-Chemical, 218, 2004, 141.

• I. Kureshy, N.H. Khan, S.H. R. Abdi, A. P. Vyas, I. Ahmad, S. Singh, R. V. Jasra, Enantioselective Epoxidation of Non-Functionalised Alkenes catalysed by recyclable new Homo Chiral Dimeric Mn(III) Salen complexes, Journal of Catalysis, 224, 2004, 229.

• I. Kureshy, N. H. Khan, S. H. R. Abdi, I. Ahmad, S. Singh, and R. V. Jasra, Immobilization of dicationic Mn(III) salen in the interlayers of montmorrillonite Clay for enantioselective epoxidation of non-functionalised alkenes, Catalysis Letters, 91, 2003, 207.

Selected International Events:

• Applied Nanotechnology and Nanoscience International Conference (ANNIC), November 9-11, 2016, Barcelona, SPAIN.

• 2nd International Conference on Smart Material Research (ICSMR), September 22-24, 2016, Istanbul, TURKEY.

• Emirates Foundation’s Think Science Competition, April 17-19, 2016, World Trade Center, Dubai, UAE.

• SSL Visiting Fellow 2013-15 at the International Centre for Materials Science, JNCASR, SSL, Bangalore, INDIA.

• Global Conference on Materials Sciences (GC-MAS-2014), November 13-15, 2014, Antalya, TURKEY.

• 5th Annual International Workshop on Advanced Material (IWAM 2013), organized by Ras Al Khaimah Center for Advance Materials (RAK CAM), Feb. 24-26, 2013 at Al Hamra Fort Hotel, Ras Al Khaimah, UAE.

• Internal Quality Assurance in Higher Education Institutions workshop organized by the Commission for Academic Accreditation (CAA)- 2nd May 2011, Alghurair University campus, Dubai, UAE.

• 45th American Chemical Society (ACS) Midwest Regional meeting, Oct. 27-30, 2010, Wichita, Kansas, USA.

• 55th Annual American Chemical Society (ACS) PentaSectional Meeting- Biofuel, April 10, 2010, organized by American Chemical Society (ACS), Norman, Oklahoma, USA.

• 18th International Symposium on Olefin Metathesis and Related Chemistry (ISOM XVIII), Organized by the Leibniz-Institute for Surface modification (IOM), August 2-7, 2009, Leipzig, GERMANY.

• 16th International Symposium on Homogeneous Catalysis (ISHC-XVI), July 6-11, 2008, Organized by the Institute of Chemistry of Organometallic Compounds (ICCOM) of the Italian Research Council (CNR) held in Florence, ITALY.

• European IDECAT Summer School on Computational Methods for Catalysis and Materials Science, 15-22 September 2007, Porquerolles, FRANCE.

• 8th Netherland’s Catalysis and Chemistry Conference (NCCC), March 5-7, 2007, Noordwijkerhout, The NETHERLANDS.

• 7th International Symposium on Catalysis Applied to Fine Chemicals organized by German Catalysis Society and Dechema. Oct 23-27, 2005, Bingen -Mainz, GERMANY.

• 1st Indo- German Conference on Catalysis-A Cross Disciplinary Vision, February 6-8, 2003, Indian Institute of Chemical Technology (IICT), Hyderabad, INDIA.

The Food and Drug Administration (FDA) has approved several quinazoline derivatives for clinical use as anticancer drugs. These include gefitinib, erlotinib, lapatinib, afatinib, and vandetanib (Fig.1) [43]. Gefitinib (Iressa®) was approved by the FDA in 2003 for the treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) in patients after failure of both platinum-based and/or docetaxel chemotherapies. In 2004, erlotinib (Tarceva®) was approved by the FDA for treating NSCLC. Furthermore, in 2005, the FDA approved erlotinib in combination with gemcitabine for treatment of locally advanced, unrespectable, or metastatic pancreatic cancer. Erlotinib acts as a reversible tyrosine kinase inhibitor. Lapatinib (Tykreb®) was approved by the FDA in 2012 for breast cancer treatment. It inhibits the activity of both human epidermal growth factor receptor-2 (HER2/neu) and epidermal growth factor receptor (EGFR) pathways. Vandetanib (Caprelsa®) was approved by the FDA in 2011 for the treatment of metastatic medullary thyroid cancer. It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor (VEGFR), EGFR, and rearranged during transfection (RET)-tyrosine kinase (TK). Afatinib (Gilotrif®) was approved by the FDA in 2013 for NSCLC treatment. It acts as an irreversible covalent inhibitor of the receptor tyrosine kinases (RTK) for EGFR and erbB-2 (HER2).

An insight into the therapeutic potential of quinazoline derivatives as anticancer agents

Shagufta*a  and  Irshad Ahmad*a 

*Corresponding authors

aDepartment of Mathematics and Natural Sciences, School of Arts and Sciences, American University of Ras Al Khaimah, Ras Al Khaimah, United Arab Emirates
E-mail: shagufta.waseem@aurak.ac.ae, iahmad@aurak.ac.ae

Abstract

Cancer is one of the major causes of worldwide human mortality. A wide range of cytotoxic drugs are available on the market, and several compounds are in different phases of clinical trials. Many studies suggest that these cytotoxic molecules are also associated with different types of adverse side effects; therefore researchers around the globe are involved in the development of more efficient and safer anticancer drugs. In recent years, quinazoline and its derivatives have been considered as a novel class of cancer chemotherapeutic agents that show promising activity against different tumors. The aim of this article is to comprehensively review and highlight the recent developments concerning the anticancer activity of quinazoline derivatives as well as offer perspectives on the development of novel quinazoline derivatives as anticancer agents in the near future.

http://pubs.rsc.org/en/Content/ArticleLanding/2017/MD/C7MD00097A?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+rss%2FMD+%28RSC+-+Med.+Chem.+Commun.+latest+articles%29#!divAbstract

An insight into the therapeutic potential of quinazoline derivatives as anticancer agents

Med. Chem. Commun., 2017, Advance Article
DOI: 10.1039/C7MD00097A, Review Article

Shagufta, Irshad Ahmad
This article reviews the recent advances in the development of quinazoline derivatives as anticancer agents.

Dr. Shagufta Waseem

Dr. Shagufta Waseem

ASSISTANT PROFESSOR – CHEMISTRY

Department of Mathematics and Natural Sciences, School of Arts and Sciences, American University of Ras Al Khaimah, Ras Al Khaimah, United Arab Emirates

Biography

Office No.: C42

Phone: Tel. Ext. 1331

Email: shagufta.waseem@aurak.ac.ae

Biography

Dr. Shagufta joined the American University of Ras Al Khaimah as an Assistant Professor of Chemistry in the School of Arts and Sciences in August 2014. Prior to joining AURAK, Dr. Shagufta worked as an Adjunct Assistant Professor of Chemistry at the University of Modern Sciences, Dubai and American University of Ras Al Khaimah, UAE.

Dr. Shagufta also worked as a Postdoctoral Researcher Associate at the Department of Chemistry and Biochemistry, Oklahoma University, USA. She developed the noble drug delivery system for breast cancer drugs using carbon nanotubes and acquired the significant experience in nanotechnology and synthetic organic chemistry. She was appointed as a Postdoctoral Research Fellow and Visiting Scientist at Leiden/Amsterdam Centre for Drug Research (LACDR), Leiden, The Netherlands. Her research interest was In silico prediction and clinical evaluation of the cardiotoxicity of drug candidates. She was focused to identify chemical substructures as ‘chemical alerts’ that interact with this hERG channel.  Dr. Shagufta received a Ph.D. under the prestigious CSIR-JRF and SRF research fellowship in Chemistry from Central Drug Research Institute (CDRI)/Lucknow University, India in 2008, her PhD research work was in the field of estrogens and antiestrogens, design and synthesis of steroidal and non-steroidal tissue selective estrogen receptor modulators (SERMs) for breast cancer, 3D-QSAR CoMFA and CoMSIA studies and analysis of pharmaceutical important molecules.

Dr. Shagufta has published 20 articles in peer-reviewed International journals of Royal Society of Chemistry, Elsevier, Wiley and Springer. Dr. Shagufta teaches courses such as General chemistry, Organic Chemistry, Chemistry in Everyday Life, and Spectroscopy along with laboratory courses.

Research and Publication

Research Interest-Dr. Shagufta 

Organic Chemistry, Medicinal Chemistry focused on Breast Cancer and Osteoporosis, Heterogeneous catalysis and Nanotechnology.

Publications- Dr. Shagufta 

1. Irshad Ahmad and Shagufta. 2015. Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of estrogen-dependent breast cancer. European Journal of Medicinal Chemistry, 102, 375-386.

2. Irshad Ahmad and Shagufta. 2015. Sulfones: An important class of organic compounds with diverse biological activities. International Journal of Pharmacy and Pharmaceutical Sciences, 7 (3), 19-27.

3. Priyanka Singh, Subal Kumar Dinda, Shagufta, Gautam Panda. 2013. Synthetic approach towards trisubstituted methanes and a chiral tertiary α-hydroxyaldehyde, possible intermediate for tetrasubstituted methanes. RSC Adv.(Royal Society of Chemistry) 3, 12100-12103. [ISSN: 2046-2069] 

4. Donna J. Nelson, Shagufta, Ravi Kumar. 2012. Characterization of a tamoxifen-tethered single-walled carbon nanotube conjugate by using NMR spectroscopy. Anal. Bioanal. Chem.[Springer] 404:771–776. [ISSN: 1618-2642]

5. Donna J. Nelson, Ravi Kumar, Shagufta. 2012. Regiochemical reversals in nitrosobenzene reactions with carbonyl compounds – α-aminooxy ketone versus α-hydroxyamino ketone products. Eur. J. Org. Chem.(Wiley-VCH) 6013-6020. [ISSN: 1099-0690]

6. Munikumar R. Reddy, Elisabeth Klaasse, Shagufta, Adriaan P. IJzerman, Andreas Bender. 2010. Validation of an in silico hERG model and its applications to the virtual screening of commercial compound databases. Chem. Med. Chem. (Wiley-VCH)5: 716-729. [ISSN: 1860-7187] 

7. Shagufta, Dong Guo, Elisabeth Klaasse, Henk de Vries, Johannes Brussee, Lukas Nalos, Martin B Rook, Marc A Vos, Marcel AG van der Heyden and Adriaan P. IJzerman. 2009. Exploring the chemical substructures essential for hERG K+ channel blockade by synthesis and biological evaluation of dofetilide analogues. Chem. Med. Chem.(Wiley-VCH) 4:1722-1732. [ISSN: 1860-7187]

8. Shagufta, Ritesh Singh and Gautam Panda. 2009, Synthetic studies towards steroid-amino acid hybrids. Indian Journal of Chemistry.(Indian Science) 48B: 989-995. [ISSN: 0975-0983]

9. Maloy K. Parai, Shagufta, Ajay K. Srivastava, Matthias Kassack, Gautam Panda. 2008. An unexpected reaction of phosphorous tribromide on chromanone, thiochromanone, 3,4-dihydro-2H-benzo[b]thiepin-5-one, 3,4-dihydro-2H-benzo[b]oxepin-5-one and tetralone derived allylic alcohols: a case study. Tetrahedron (Elsevier)64: 9962-9976. [ISSN: 0040-4020]

10. Gautam Panda, Maloy Kumar Parai, Sajal Kumar Das, Shagufta, Manish Sinha, Vinita Chaturvedi, Anil K. Srivastava, Anil N. Gaikwad, Sudhir Sinha. 2007. Effect of substituents on diarymethanes for antitubercular activity. European Journal of Medicinal Chemistry (Elsevier) 42: 410-419. [ISSN: 0223-5234]

11. Shagufta and Gautam Panda. 2007. A new example of a steroid-amino acid hybrid: Construction of constrained nine membered D-ring steroids. Organic and Biomolecular Chemistry (Royal Society of Chemistry) 5 : 360- 366. [ISSN 1477-0539]

12. Shagufta, Ashutosh Kumar, Gautam Panda and Mohammad Imran Siddiqi. 2007. CoMFA and CoMSIA 3D-QSAR analysis of diaryloxy methano phenanthrene derivatives as anti- tubercular agents. Journal of Molecular Modeling (Springer) 13: 99-107. [ISSN:0948-5023]

13. Shagufta, Ajay Kumar Srivastava, Ramesh Sharma, Rajeev Mishra, Anil K. Balapure, Puvvada S. R. Murthy and Gautam Panda. 2006. Substituted phenanthrenes with basic amino side chains: A new series of anti-breast cancer agents. Bioorganic and Medicinal Chemistry (Elsevier) 14: 1497-1505. [ISSN: 0968-0896]

14. Shagufta, Ajay Kumar Srivastava and Gautam Panda. 2006. Isomerization of allylic alcohols into saturated carbonyls using phosphorus tribromide. Tetrahedron Letters (Elsevier) 47: 1065-1070. [ISSN: 0040-4039]

15. Gautam Panda, Jitendra K. Mishra, Shagufta, T. C. Dinadayalane and G. Narahari Sastry & Devendra S Negi. 2006. Hard-soft acid-base (HSAB) principle and difference in d-orbital configurations of metals explain the regioselectivity of nucleophilic attack to a carbinol in Friedel-Crafts reaction catalyzed by Lewis and protonic acids. Indian Journal of Chemistry (Indian Science)45B: 276-287. [ISSN: 0975-0983]

16. Shagufta, Maloy Kumar Parai and Gautam Panda. 2005. A new strategy for the synthesis of aryl- and heteroaryl-substituted exocyclic olefins from allyl alcohols using PBr3. Terahedron Letters (Elsevier) 46: 8849-8852. [ISSN: 0040-4039]

17. Shagufta, Resmi Raghunandan, Prakash R. Maulik and Gautam Panda. 2005. Convenient phosphorus tribromide induced syntheses of substituted 1-arylmethylnaphthalenes from 1-tetralone derivatives. Tetrahedron Letters (Elsevier) 46: 5337-5341. [ISSN: 0040-4039]

18. Gautam Panda, Shagufta, Anil K. Srivastava and Sudhir Sinha. 2005. Synthesis and antitubercular activity of 2-hydroxy-aminoalkyl derivatives of diaryloxy methano phenanthrenes. Bioorganic and Medicinal Chemistry Letters (Elsevier) 15: 5222-5225. [ISSN: 0960-894X]

19. Sajal Kumar Das, Shagufta, and Gautam Panda. 2005. An easy access to unsymmetric trisubstituted methane derivatives (TRSMs). Tetrahedron Letters (Elsevier) 46: 3097-3102. [ISSN: 0040-4039]

20. Shagufta, Jitendra Kumar Mishra, Vinita Chaturvedi, Anil K. Srivastava, Ranjana Srivastava and Brahm S. Srivastava. 2004. Diaryloxy methano phenanthrenes: a new class of antituberculosis agents. Bioorganic and Medicinal Chemistry (Elsevier) 12: 5269-5276. [ISSN: 0968-0896

The Food and Drug Administration (FDA) has approved several quinazoline derivatives for clinical use as anticancer drugs. These include gefitinib, erlotinib, lapatinib, afatinib, and vandetanib (Fig.1) [43]. Gefitinib (Iressa®) was approved by the FDA in 2003 for the treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) in patients after failure of both platinum-based and/or docetaxel chemotherapies. In 2004, erlotinib (Tarceva®) was approved by the FDA for treating NSCLC. Furthermore, in 2005, the FDA approved erlotinib in combination with gemcitabine for treatment of locally advanced, unrespectable, or metastatic pancreatic cancer. Erlotinib acts as a reversible tyrosine kinase inhibitor. Lapatinib (Tykreb®) was approved by the FDA in 2012 for breast cancer treatment. It inhibits the activity of both human epidermal growth factor receptor-2 (HER2/neu) and epidermal growth factor receptor (EGFR) pathways. Vandetanib (Caprelsa®) was approved by the FDA in 2011 for the treatment of metastatic medullary thyroid cancer. It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor (VEGFR), EGFR, and rearranged during transfection (RET)-tyrosine kinase (TK). Afatinib (Gilotrif®) was approved by the FDA in 2013 for NSCLC treatment. It acts as an irreversible covalent inhibitor of the receptor tyrosine kinases (RTK) for EGFR and erbB-2 (HER2).

An insight into the therapeutic potential of quinazoline derivatives as anticancer agents

Shagufta*a  and  Irshad Ahmad*a 

*Corresponding authors

aDepartment of Mathematics and Natural Sciences, School of Arts and Sciences, American University of Ras Al Khaimah, Ras Al Khaimah, United Arab Emirates
E-mail: shagufta.waseem@aurak.ac.ae, iahmad@aurak.ac.ae

Abstract

Cancer is one of the major causes of worldwide human mortality. A wide range of cytotoxic drugs are available on the market, and several compounds are in different phases of clinical trials. Many studies suggest that these cytotoxic molecules are also associated with different types of adverse side effects; therefore researchers around the globe are involved in the development of more efficient and safer anticancer drugs. In recent years, quinazoline and its derivatives have been considered as a novel class of cancer chemotherapeutic agents that show promising activity against different tumors. The aim of this article is to comprehensively review and highlight the recent developments concerning the anticancer activity of quinazoline derivatives as well as offer perspectives on the development of novel quinazoline derivatives as anticancer agents in the near future.

http://pubs.rsc.org/en/Content/ArticleLanding/2017/MD/C7MD00097A?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+rss%2FMD+%28RSC+-+Med.+Chem.+Commun.+latest+articles%29#!divAbstract

An insight into the therapeutic potential of quinazoline derivatives as anticancer agents

Med. Chem. Commun., 2017, Advance Article
DOI: 10.1039/C7MD00097A, Review Article

Shagufta, Irshad Ahmad
This article reviews the recent advances in the development of quinazoline derivatives as anticancer agents.

//////////

DR PRAVIN PATIL

Dr. Pravin C. Patil

Postdoctoral Research Associate at University of Louisville

LINKS

Email

pravinchem@gmail.comhttps://www.researchgate.net/profile/Pravin_Patil18/infohttps://www.linkedin.com/in/dr-pravin-c-patil-80741a5/https://www.facebook.com/pravinchem?lst=100000982203141%3A100002955527551%3A1492682395

• Dr. Pravin C Patil completed his B.Sc. (Chemistry) at ASC College Chopda (Jalgaon, Maharashtra, India) in 2001 and M.Sc. (Organic Chemistry) at SSVPS’S Science College Dhule in North Maharashtra University (Jalgaon, Maharashtra, India) in year 2003.  
  
  
  During his research experience, he has authored 23 international publications in peer reviewed journals and inventor for 4 patents.
• After M.Sc. degree he was accepted for summer internship training program at Bhabha Atomic Research Center (BARC, Mumbai) in the laboratory of Prof. Subrata Chattopadhyay in Bio-organic Division. 
• In 2003, Dr. Pravin joined to API Pharmaceutical bulk drug company, RPG Life Science (Navi Mumbai, Maharashtra, India) and worked there for two years. In 2005, he enrolled into Ph.D. (Chemistry) program at Institute of Chemical Technology (ICT), Matunga, Mumbai, Maharashtra, under the supervision of Prof. K. G. Akamanchi in the department of Pharmaceutical Sciences and Technology. 
• After finishing Ph.D. in 2010, he joined to Pune (Maharashtra, India) based pharmaceutical industry, Lupin Research Park (LRP) in the department of process development. 
• After spending two years at Lupin as a Research Scientist, he got an opportunity in June 2012 to pursue Postdoctoral studies at Hope College, Holland, MI, USA under the supervision of Prof. Moses Lee. During year 2012-13 he worked on total synthesis of achiral anticancer molecules Duocarmycin and its analogs. 
• In 2014, he joined to Prof. Frederick Luzzio at the Department for Chemistry, University of Louisville, Louisville, KY, USA to pursue postdoctoral studies on NIH sponsored project “ Structure based design and synthesis of Peptidomimetics targeting P. gingivalis.
• During his research experience, he has authored 23 international publications in peer reviewed journals and inventor for 4 patents.
• 
  
• Ph.D. Organic chemist with significant experience in the field of academic research, postdoctoral studies and pharmaceutical industries.
  
  Specialties: 
  1. Good theory and practical knowledge of Organic Chemistry.
  2. Expertise in chiral resolution, racemization, purification techniques such as extraction, distillation, recrystallization and column chromatography.
  3. Worked on various organic reactions like Vilsmeier-Haack reaction, Knoevenagel condensation, Friedal-Crafts alkylation and acylation, Suzuki Coupling, Aldol condensation, Knorr Pyrrole synthesis, Grignard reaction, Oxidation, Reduction, Diazotization, Reductive alkylation, Hydrogenation etc.
  4. Expertise in multi-step organic synthesis of heterocyclic compounds based on quinoxaline, coumarin, benzoxazole, benzothiazole, benzimidazole, pyrroles, thiazole, pyridine, oxazole, thiophene, imidazole etc from milligram to kilogram scale.
  5. Experience in route scouting, route selection, process development, optimization, technology transfer to pilot plant and bulk synthesis of active pharmaceutical ingredients (APIs). 
  6. Expertise in literature survey using Sci-Finder, Cross Fire Beilstein, Chemical Abstracts (CA), Patents.
  7. Aware about the knowledge and functions of all spectroscopic techniques and instrumentation which are the essential part of research
• 
  

HIGHLIGHTS
• Strong background in organic reaction mechanisms and contemporary synthetic methods.
• Wide range of experience in route scouting, optimization, process development, scale up, technology transfer and commercialization of APIs and intermediates.
• Experience in multi step organic synthesis of NCE molecules for pre-clincal trials following GMP guidelines.
• Expertise in synthesis of heterocyclic compounds based on oxazoles, coumarin, benzoxazole, benzothiazole, benzimidazole, highly sensitive pyrroles, thiazole, thiophene, imidazole.
• Characterization / Identification of API Impurities as a part of DMF filing process.
• Experience in laboratory scale high pressure reactions and catalytic hydrogenation.
• Expertise in techniques routinely used in synthetic organic chemistry laboratories, including analytical, preparative, and spectroscopic techniques like nuclear magnetic resonance, mass, infrared and purification techniques such as flash chromatography, recrystallization.
• Experience in writing scientific manuscripts, mentoring undergraduate students/Junior colleagues.



Current

• Works at University of Louisville, Hope College and Lupin Ltd

  Past: Lupin Ltd and RPG Life Sciences
• 
  

  Studied at Mumbai University Institute of Chemical Technology

  Past: Institue of Chemical Technology, Mumbai and Institute of Chemical Technology ( UDCT), Mumbai
• 
  

  Lives in Louisville, Kentucky

  From Chopda

Experience

• 

  Postdoctoral Research Associate

  Company NameUniversity of Louisville

  Dates EmployedJan 2014 – Present

  
  

  Employment Duration3 yrs 4 mos

  LocationLouisville, Kentucky Area

• 

  Postdoctoral Fellow in Chemistry

  Company NameHope College

  Dates EmployedJun 2012 – Dec 2013

  
  

  Employment Duration1 yr 7 mos

  LocationGreater Grand Rapids, Michigan Area
• 

  Research Scientist

  Company NameLupin Research Park

  Dates EmployedMay 2010 – Jun 2012

  
  

  Employment Duration2 yrs 2 mos

  LocationPune Area, India
• 

  Ph.D. (Sci.)

  Company NameInstitute of Chemical Technology (ICT), Mumbai

  Dates EmployedOct 2005 – Feb 2010

  
  

  Employment Duration4 yrs 5 mos
• 

  Research Officer

  Company NameRPG Life Sciences

  Dates EmployedSep 2003 – Oct 2005

  
  

  Employment Duration2 yrs 2 mos
• 

  Project Assistant

  Company NameBhabha Atomic Research Centre

  Dates EmployedJul 2003 – Sep 2003

  
  

  Employment Duration3 mos

Education

• 

  University of Mumbai

  Degree NamePh.D.(Chemistry)

  Field Of StudySynthetic Chemistry

  Dates attended or expected graduation2006 – 2009
  A great opportunity to work here as once it was a dream for me, but now it made me a proud to be a part of UD inside as well as outside its campus. Learned the things how to overcome on problems of any type by considering the limit of time and situation. The Ph.D experience helped to gained the knowledge of process chemistry and its important parameters to study with.
• 

  North Maharashtra University

  Degree NameM.Sc.

  Field Of StudyOrganic Chemistry

  Dates attended or expected graduation2001 – 2003
• 

  North Maharashtra University

  Degree NameB.Sc.

  Field Of StudyChemistry

  Dates attended or expected graduation1998 – 2001

Tetrahedron Letters

14

Publications

• publication titleSynthesis of extended oxazoles II: Reaction mniolds of 2-(halomethyl)-4,5 diaryloxazoles.

  publication descriptionTetrahedron Letters
  publication dateJan 10, 2016

  Authors

  

• publication title

  AzaHx, a novel fluorescent, DNA minor groove and G·C recognition element: Synthesis and DNA binding properties of a p-anisyl-4-aza-benzimidazole-pyrrole-imidazole (azaHx-PI) polyamide
  publication descriptionBioorganic Medicinal Chemistry Letters
  publication dateSep 1, 2015

  Authors

  

• publication title

  Nuclear Localization and Gene Expression Modulation by a Fluorescent Sequence Selective p-Anisylbenzimidazolecarboxamido Imidazole-Pyrrole Polymide
  publication descriptionChemistry and Biology
  publication dateJul 23, 2015

  Authors

  

• publication title

  Oxazoles for click chemistry II: synthesis of extended heterocyclic scaffolds
  publication descriptionTetrahedron Letters
  publication dateNov 8, 2014

  Authors

  

• publication title

  Simple and effective route for synthesis of parvaquone, an antiprotozoal drug
  publication descriptionRSC Advances
  publication dateOct 20, 2014

  Authors

  

• publication title

  Inhibition of Human Glutathione Transferases by Dinitronaphthalene Derivatives
  publication descriptionArchives of Biochemistry and Biophysics
  publication dateJun 12, 2014

  Authors

  

Dr. Pravin has 4 patents4

Patents

• Patent titleA novel method for the synthesis of 2-alkyl-3-hydroxy -1, 4-naphthoquinones

  Patent issuer and numberin 2007/IN1474/MUM2007
  Patent dateIssued 2007

  Contributors

  

• Patent titleBisulphite adduct of Donepezil intermediate

  Patent issuer and numberin IN1164/KOL/2010
  Patent dateFiled 2012

  Contributors

  

• Patent title

  A novel method for synthesis of Parvaquon
  Patent issuer and numberin IN 2678/Mum/2009
  Patent dateFiled 2009

  Contributors

  

• Patent title

  Process for preparation of methyl –(+)-(S)-Alpha-(2-chlorophenyl)-6,7-dihydrothieno [3,2-C] pyridine-5(4H)-acetic acid methyl esters or salts thereof having higher chiral purity and products thereof.
  Patent issuer and numberus US2010/0004453A1

Dr. Pravin has 2 honors2

Honors & Awards

• honor titleSenior Research Fellowship

  honor dateDec 2007
  honor issuerWorld Bank through TEQIP Programe

• honor titleJunior Research Fellowship

  honor dateDec 2005
  honor issuerWorld Bank through TEQIP Programe

PATENTS
1. Bisulphite adduct of Donepezil intermediate. Patil, Pravin; Lande, Hemraj; Singh, Gurvinder pal; Ray Purna. Lupin Ltd, From Indian (2010), IN 1164/KOL/2010.
2. Process for preparation of methyl –(+)-(S)-Alpha-(2-chlorophenyl)-6,7-dihydrothieno [3,2-C] pyridine-5(4H)-acetic acid methyl esters or salts thereof having higher chiral purity and products thereof. By Srivasatava, Anita Ranjan; Pawar, Prashant Pandurang; Poojari, Krishna Anand; Patil, Pravin Chaitram; Dalvi, Rajiv Ramchandra. RPG Life Sciences: US2010/0004453 A1.
3. A novel method for the synthesis of 2-alkyl-3-hydroxy -1, 4-naphthoquinones. Patil, Pravin C. and Akamanchi, Krishnacharya G. From Indian (2007), IN 1474/ Mum/ 2007.

AWARDS/FELLOWSHIPS
• Outstanding Performance Year Award (2010-2011) by Lupin Ltd.(Research Park) Pune, India.
• Senior Research Fellowship (2008-2009) by World Bank through TEQIP (Technical Education Quality Improve Programe) at Institute of Chemical Technology, Mumbai, India.
• Junior Research Fellowship (2005-2008) by World Bank through TEQIP (Technical Education Quality Improve Programe) by Institute of Chemical Technology, Mumbai, India.
• Nominated for Best Ph.D. Student in Institute of Chemical Technology, Mumbai, Maharashtra, India for the years 2007-08 and 2009-10.
• Ranked in top 5% in Master (M. Sc.) and Bachelor (B. Sc.) examinations at university level.

• 
  
• Postdoctoral Researcher at Hope College
• 
  

  Worked at Lupin Ltd, Worked at RPG Life Sciences, 
• 
  

  Worked at ICT Group, Studied at Institute of Chemical Technology ( UDCT), Mumbai, 
• 
  

  Lives in Louisville, Kentucky

An honor to be invited at book inauguration " Publish and Flourish" by Prof. Stephen K Taylor at Hope College

AT ICT MATUNGA MUMBAI INDIA

MEMORIES
I was Postdoc at Hope college during June 2012-Dec 2013. Chemistry department of Hope college has tradition to take annual photo of faculty / staff to upload on department website. This one was from year 2012 and the another one from year 2013. I am grateful to all those eminent faculties for considering me as a part of Hope family almost everyday.

Dream come true !!

Photo and 15 min talk with Prof. Peter Agre (Nobel Laureate- 2003) at Department of Chemistry, University of Louisville, Louisville, Kentucky, USA...below

//////////////